- Home
- BETR vs ADCT Comparison
BETR vs ADCT Comparison
Compare BETR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BETR | ADCT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.2M | 484.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BETR | ADCT |
|---|---|---|
| Price | $33.18 | $4.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $7.50 |
| AVG Volume (30 Days) | 310.7K | ★ 784.0K |
| Earning Date | 01-01-0001 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,837,000.00 |
| Revenue This Year | $50.32 | $14.96 |
| Revenue Next Year | $64.07 | $1.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.84 |
| 52 Week Low | $8.90 | $1.05 |
| 52 Week High | $94.06 | $4.80 |
Technical Indicators
Market Signals| Indicator | BETR | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 53.63 |
| Support Level | $32.23 | $3.25 |
| Resistance Level | $35.07 | $4.71 |
| Average True Range (ATR) | 3.29 | 0.25 |
| MACD | 0.59 | -0.02 |
| Stochastic Oscillator | 73.87 | 36.90 |
Price Performance
Historical ComparisonAbout BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).